Pfizer Limited has officially scheduled a Board of Directors meeting for Tuesday, May 12, 2026. The board is set to review and approve the financial results for both the final quarter (Q4) and the full financial year ending March 31, 2026. Additionally, the company will deliberate on the potential recommendation of a dividend for the completed financial year, providing key updates to its shareholders.
Upcoming Board Meeting Agenda
The management of Pfizer Limited has convened a board meeting to be held on May 12, 2026. The primary focus of this assembly is to finalize and take on record the company’s financial performance for the period ending March 31, 2026. This covers the final quarter of the 2025-26 financial year as well as the annual performance metrics.
Dividend Consideration
Beyond reviewing quarterly and annual earnings, the board will evaluate a proposal for a dividend payment for the financial year concluded on March 31, 2026. If approved, this would represent a key distribution of capital to shareholders, reflecting the company’s fiscal health for the year.
Trading Window Update
In accordance with internal corporate governance policies, the trading window for company shares was restricted starting March 31, 2026. This closure remains in effect to ensure market integrity and will lift 48 hours following the official public disclosure of the financial results on May 12, 2026.
Source: BSE
